Crestwood Advisors Group’s InMed Pharmaceuticals INM Stock Holding History

Crestwood Advisors Group’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.1K	Buy	+14,900	New	+$16.5K	﹤0.01%	875

Other funds holding INM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Crestwood Advisors Group's INM Position: Q2 2026 in Review

Crestwood Advisors Group opened a new position in InMed Pharmaceuticals (INM) in Q2 2026: 14,900 shares worth $23.1K. The stake represents ﹤0.01% of the portfolio and ranks #875 among its holdings.

20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

Crestwood Advisors Group held 14,900 shares of InMed Pharmaceuticals worth $23.1K as of Q2 2026.
InMed Pharmaceuticals was a new Crestwood Advisors Group position in Q2 2026.
InMed Pharmaceuticals made up ﹤0.01% of Crestwood Advisors Group's portfolio in Q2 2026, its #875 holding.
20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Crestwood Advisors Group's 13F filing for Q2 2026, filed 3 Aug 2026.